Panitumumab is a monoclonal antibody used primarily in the treatment of metastatic colorectal cancer. It targets the epidermal growth factor receptor (EGFR), which plays a critical role in the growth and survival of cancer cells. The market for Panitumumab is part of the broader oncology and biologics markets.
The Panitumumab market is expected to grow at a compound annual growth rate (CAGR)...
English
Arabic
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian